Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay

被引:3
作者
Cheng, JWM
Charland, SL
Shaw, LM
Kobrin, S
Goldfarb, S
Stanek, EJ
Spinler, SA
机构
[1] PHILADELPHIA COLL PHARM & SCI,PHILADELPHIA,PA 19104
[2] ARNOLD & MARIE SCHWARTZ COLL PHRMA & HLTH SCI,BROOKLYN,NY
[3] PHILADELPHIA COLL PHARM & SCI,PHILADELPHIA,PA 19104
[4] UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104
[5] UNIV PENN,RENAL ELECTROLYTE DIV,PHILADELPHIA,PA 19104
[6] UNIV PENN,DEPT MED,CARDIOVASC SECT,PHILADELPHIA,PA 19104
[7] KAISER PERMANENTE,ST JOSEPHS HOSP,DEPT PHARM,DENVER,CO
来源
PHARMACOTHERAPY | 1997年 / 17卷 / 03期
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To determine digoxin pharmacokinetics in subjects with different degrees of renal function using fluorescence polarization immunoassay (FPIA), which is associated with less interference from digoxin-like immunoreactive substances (DLIS) than radioimmunoassay. Setting. University hospital clinical research center. Participants. Eighteen subjects (mean age 44 yrs) with different degrees of renal function: group 1, creatinine clearance (Cl-cr) below 10 ml/minute; group 2, Cl-cr 10-50 ml/minute; and group 3, Cl-cr greater than SO ml/minute (6 patients in each group). Intervention. Over 5-7 days, 15 serum samples were collected after a single intravenous dose of digoxin 7 or 10 mu g/kg actual body weight (WT) for serum concentration measurements by FPIA. Two-compartment pharmacokinetic parameters (zero-rime intercept of the concentration-time curve of the initial distribution phase [A], zero-lime intercept of the concentration-lime curve of the terminal elimination phase [B], initial distribution phase constant [alpha], terminal elimination rate constant [beta], volume of distribution in the central compartment [V-c] and at steady slate [V-c], total body clearance [Cl], mean residence time [MRT], area under the concentration-rime curve [AUC]) were determined using a nonlinear least squares regression program. Measurements and Main Results. No significant differences were found among groups for A, B, alpha, beta, beta-half-life, V-c/WT, MRT, AUG, and Cl/WT. Significant differences were observed in V-ss/WT (4.8 +/- 1.0, 6.6 +/- 0.5, 6.4 +/- 0.7 L/kg) between group I versus group 2 and group 1 versus group 3 (p<0.01). Measured Cl-cr was correlated with Cl (r(2)=0.40, p<0.01), Cl/WT (r(2)=0.29, p<0.05), V-ss (r(2)=0.35, p=0.01), and V-ss/WT (r(2)=0.24, p<0.05). Conclusion. This study confirmed that V-ss is smaller in patients with chronic renal failure (Cl-cr < 10 ml/min) than those without chronic renal failure. Therefore, previous recommendations that lower digoxin loading doses should be administered in patients with renal failure are applicable to digoxin serum concentration monitoring using FPIA.
引用
收藏
页码:584 / 590
页数:7
相关论文
共 36 条
[1]   ALTERED DISTRIBUTION OF DIGOXIN IN RENAL-FAILURE - CAUSE OF DIGOXIN TOXICITY [J].
ARONSON, JK ;
GRAHAMESMITH, DG .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 3 (06) :1045-1051
[2]   CLINICAL PHARMACOKINETICS OF CARDIAC-GLYCOSIDES IN PATIENTS WITH RENAL DYSFUNCTION [J].
ARONSON, JK .
CLINICAL PHARMACOKINETICS, 1983, 8 (02) :155-178
[3]   STATISTICAL ESTIMATIONS IN PHARMACOKINETICS [J].
BOXENBAU.HG ;
RIEGELMA.S ;
ELASHOFF, RM .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1974, 2 (02) :123-148
[4]   EVALUATION AND COMPARISON OF THE TDXII, STRATUS, AND OPUS DIGOXIN ASSAYS [J].
DODDS, HM ;
NORRIS, RLG ;
JOHNSON, AG ;
POND, SM .
THERAPEUTIC DRUG MONITORING, 1995, 17 (01) :68-74
[5]  
GAULT MH, 1986, CLIN CHEM, V32, P2000
[6]  
GAULT MH, 1985, CLIN CHEM, V31, P1272
[7]  
GAULT MH, 1979, CLIN PHARMACOL THER, V25, P499
[8]  
GAULT MH, 1976, NEPHRON, V17, P161
[9]   DIGITALIS AND RENAL-FAILURE [J].
GAULT, MH .
INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1988, 11 (03) :141-143
[10]   QUESTION OF CUMULATION OF DIGOXIN METABOLITES IN RENAL-FAILURE [J].
GIBSON, TP ;
NELSON, HA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (02) :219-223